WHAN IN PHARM CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,810 KRW | +0.15% |
|
+0.36% | -8.18% |
| 2023 | Whan In Pharm Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2015 | Whanin Pharmaceutical Co. Ltd.(KOSE:A016580) added to Russell Global Index | CI |
| Sales 2024 * | 249B 182M | Sales 2025 * | 271B 198M | Capitalization | 211B 154M |
|---|---|---|---|---|---|
| Net income 2024 * | 28B 20.44M | Net income 2025 * | 30B 21.9M | EV / Sales 2024 * | 0.71 x |
| Net cash position 2024 * | 35B 25.55M | Net cash position 2025 * | 43.3B 31.61M | EV / Sales 2025 * | 0.62 x |
| P/E ratio 2024 * |
9.19
x | P/E ratio 2025 * |
8.45
x | Employees | 553 |
| Yield 2024 * |
2.17% | Yield 2025 * |
2.17% | Free-Float | 59.11% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.15% | ||
| 1 week | +0.36% | ||
| Current month | -5.02% | ||
| 1 month | -5.15% | ||
| 3 months | -4.03% | ||
| 6 months | +4.54% | ||
| Current year | -8.18% |
1 week
13 460.00
13 850.00
1 month
13 460.0014 680.00
Current year
13 460.0015 570.00
1 year
12 410.0016 400.00
3 years
12 410.0023 550.00
5 years
9 950.0023 550.00
10 years
9 950.0029 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Won-Bum Lee
CEO | Chief Executive Officer | 49 | 05-12-31 |
Kwang-Sik Lee
CEO | Chief Executive Officer | 76 | 78-05-31 |
Ho-Chul Shin
CTO | Chief Tech/Sci/R&D Officer | 51 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwang-Sik Lee
CEO | Chief Executive Officer | 76 | 78-05-31 |
Won-Bum Lee
CEO | Chief Executive Officer | 49 | 05-12-31 |
Kyung-Seok Cho
BRD | Director/Board Member | 50 | 16-03-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 13,810 | +0.15% | 7,712 |
| 24-04-22 | 13,790 | +1.47% | 12,320 |
| 24-04-19 | 13,590 | -0.88% | 30,572 |
| 24-04-18 | 13,710 | +0.07% | 10,024 |
| 24-04-17 | 13,700 | -0.22% | 11,904 |
End-of-day quote Korea S.E., April 22, 2024
More quotes
Whan In Pharm Co.,Ltd. is a Korea-based company specialized in the manufacturing of pharmaceutical products. The Companyâs products consist of antidepressants, antipsychotics, anxiolytics, hypnotics, antiepileptics, attention-deficit/hyperactivity disorder (ADHD) agents, nootropics, antiparkinson drugs, anti-dementia drugs, gastrointestinal drugs, cardiovascular drugs, immunostimulating agents, antibiotics, multi-vitamins, respiratory drugs, dermatologic drugs, antivirals, anti-diabetic agents and others. The Company also involves in the real estate rental business.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
13,810
KRW
Average target price
21,000
KRW
Spread / Average Target
+52.06%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.18% | 153M | |
| +17.88% | 44.31B | |
| +19.87% | 22.17B | |
| +13.05% | 14.62B | |
| +8.06% | 13.12B | |
| +39.21% | 11.58B | |
| -8.96% | 6.96B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +5.03% | 5.03B |
- Stock Market
- Equities
- A016580 Stock
